|Bid||4.2600 x 1100|
|Ask||6.7500 x 4000|
|Day's Range||4.5200 - 4.6700|
|52 Week Range||1.2900 - 5.0300|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities.
Positive results announced earlier this week from an early-stage study led to another day of big gains for this clinical-stage biotech.
The biotech stock is enjoying a second day of big gains after the company reported promising results for experimental drug ACH-5228.
The study also included a single dose cohort of 240 mg. The results demonstrated that ACH-5228, when dosed 120 mg BID or higher, achieved near complete and sustained Alternative Pathway (AP) inhibition with a mean value of 95% at steady state concentrations as measured by AP Hemolysis and AP Wieslab assays. With its improved potency and longer durability of effect, we believe that oral ACH-5228 has the potential to be the best-in-class alternative pathway inhibitor. Danicopan, our first-generation alternative pathway inhibitor, validated factor D as a target and we plan to begin a Phase 3 registrational study in early 2020,” said Joe Truitt, Chief Executive Officer of Achillion Pharmaceuticals.
Bill Mathews, founder and contributing editor to The Cheap Investor, selected Achillian Pharmaceuticals (ACHN) as a more speculative idea for 2019. The stock has risen 69%. Here's his latest update on this biotech firm.
Anyone researching Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) might want to consider the historical volatility of...
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
BLUE BELL, Pa., June 13, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH-4471 (newly designated “danicopan”) proof of concept Phase 2 trial in untreated patients with paroxysmal nocturnal hemoglobinuria (PNH) was accepted for oral presentation at the 24th Congress of the European Hematology Association (EHA). The 24th Congress of the EHA is being held in Amsterdam, Netherlands from June 13 – 16, 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019.
BLUE BELL, Pa., May 14, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
On a per-share basis, the New Haven, Connecticut-based company said it had a loss of 14 cents. The company's shares closed at $2.88. A year ago, they were trading at $3.67. _____ This story was generated ...
- PNH combo Phase 2 trial interim data to be presented May 17, 2019 -- C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND.
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.